| Filed On | Filing |
|---|---|
| 24 Jul 2025 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
THIS PURCHASE AGREEMENT (this “Agreement”) is made as of July 22, 2025, by and between the purchaser listed on Exhibit A attached hereto (the “Purchaser”) and Unity Biotechnology, Inc., a Delaware corporation (the “Company”). |
| 28 Apr 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
This filing amends Item 5.02 of the Current Report on Form 8-K filed by Unity Biotechnology, Inc. (the “Company”) with the Securities and Exchange Commission on April 11, 2023. As reported on April 11, 2023, the Company and Jamie Dananbe... |
| 07 Jul 2021 |
8-K/A: Financial Statements and Exhibits
1 UBX1325 Phase 1 Data Conference Call July 6th, 2021 Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO Exhibit 99.2 |
| 31 Jul 2020 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...